Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC

被引：0
|
作者：
Liu, L. [1 ]
Liu, J. [2 ]
Liu, Y. [1 ]
Yu, X. [2 ]
Li, S. [1 ]
Li, B. [1 ]
Guo, S. [2 ]
Zhang, Y. [3 ]
Wang, Y. [1 ]
Zheng, T. [1 ]
Han, W. [1 ]
Xie, Y. [2 ]
Zhou, L. [2 ]
Zhang, J. [2 ]
Zhao, Y. [2 ]
Li, Y. [2 ]
Hu, Y. [1 ]
Wang, J. [1 ]
Cao, H. [1 ]
机构：
[1] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[2] Shandong Publ Hlth Clin Ctr, Jinan, Peoples R China
[3] Shandong Canc Hosp, Jinan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Envafolimab; sq-NSCLC; First-line;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4.11E.06
引用
收藏
页码：S397 / S397
页数：1
相关论文
共 50 条
  • [1] Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy for NSCLC
    Miao, C.
    Yuan, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S397 - S397
  • [2] Recombinant human-endostatin combined with sintilimab and chemotherapy in first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma
    Cui, Shiyun
    Fan, Lei
    Sun, Xinnan
    Cai, Yucheng
    Wang, Ting
    Li, Ping
    Wang, Rong
    Liu, Lianke
    ONCOLOGY LETTERS, 2025, 29 (05)
  • [3] Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
    Andric, Zoran
    Galffy, Gabriella
    Dols, Manuel Cobo
    Szima, Barna
    Stojanovic, Goran
    Petrovic, Marina
    Felip, Enriqueta
    Baz, David Vicente
    Aix, Santiago Ponce
    Juan-Vidal, Oscar
    Szalai, Zsuzsanna
    Losonczy, Gyorgy
    Blanco, Antonio Calles
    Bernabe, Reyes
    Ledo, Gema Garcia
    Hernandez, Andres Aguilar
    Duecker, Klaus
    Zhou, Dongli
    Schroeder, Andreas
    Guezel, Guelseren
    Ciardiello, Fortunato
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
  • [4] First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC
    Wang, Lijie
    Gao, Ming
    Yang, Wenyu
    Wang, Chunyu
    Wang, Ting
    Jing, Fangfang
    Ma, Junxun
    Zhang, Fan
    Tao, Haitao
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma
    Si, Xiaoyan
    Wu, Shafei
    Wang, Hanping
    Zhang, Xiaotong
    Wang, Mengzhao
    Zeng, Xuan
    Zhang, Li
    THORACIC CANCER, 2018, 9 (08) : 1056 - 1061
  • [6] Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer
    Fu, Silv
    Huang, Hongxiang
    Shang, Kai
    Tu, Ganjie
    Zhong, Peiyuan
    Li, Siling
    Zhu, Xie
    Peng, Sujuan
    Liu, Yangyang
    Lu, Zhihui
    Chen, Li
    FUTURE ONCOLOGY, 2023, 19 (02) : 147 - 158
  • [7] Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC
    Thein, K.
    Jahan, N.
    Sultan, A.
    Swarup, S.
    Tun, A.
    Yendala, R.
    Ball, S.
    Hlaing, P.
    Htut, T.
    Rehman, S.
    D'Cunha, N.
    Hardwicke, F.
    Tijani, L.
    Awasthi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S472 - S473
  • [8] Study on PD-1 inhibitor combined with recombinant human endostatin and chemotherapy followed by IMRT in the treatment of advanced NSCLC
    Ma, Faqiang
    Qi, Zhengjun
    Liao, Guanghui
    Zhao, Lili
    Su, Xialu
    Dong, Changfen
    Lu, Fangyang
    Sun, Yi
    MEDICINE, 2025, 104 (06)
  • [9] Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
    Shao, Taihang
    Ren, Yinan
    Zhao, Mingye
    Tang, Wenxi
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [10] Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
    Feng, Li
    Wang, Zhicong
    Jing, Li
    Zhou, Zhiguo
    Shi, Shuai
    Deng, Ruoying
    Liu, Yibing
    Meng, Qingju
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
12345